Please assess the completion status of the following clinical trial:

Trial Title: Impact of Infant Formula on Resolution of Cow's Milk Allergy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria (to consent):~* Infants 0-120 days of age with suspected CMA, as determined by the pediatrician or specialist, will be referred to the study. A Standard Operating Procedures (SOP) document will be provided for the clinicians to help guide their referral to the study. Physician diagnosis of CMA will be based on the following:~* Physician documented, gross or persistent microscopic blood in stool (3 positive guaiac cards on three separate stools) in the absence of other explanation (e.g., fissure, moderate-to-severe constipation) AND / OR~Infant with at least one gastrointestinal, dermatological, or respiratory allergic manifestation suggestive of CMA:~* Gastrointestinal: Chronic Diarrhea, Constipation or Vomiting/Gastro-esophageal reflux~* Dermatologic: Atopic Dermatitis or Urticaria~* Respiratory: Cough, Allergic rhinitis or Recurrent Wheezing~* General:Colic / Irritability~* No change in treatment with medications during the 7 days preceding the elimination diet and no expected change in medications during the DBPCFCs (unless otherwise medically necessary)~* Signed informed consent obtained for infants participation in the study~* Signed authorization obtained to use and/or disclose Protected Health Information for infant from birth through the length of the study period~* Willingness to comply with following inclusion criteria if found to have a positive DBPCFC screen:~  1. Caregiver(s) agree to comply with the infant elimination diet given to them by the investigator for the duration of the study~ 2. Mother agrees to follow an elimination diet throughout duration of breast feeding~ 3. Parent(s) or legally authorized representative agrees not to enroll infant in another interventional clinical study while participating in this study~Inclusion Criteria (to randomization):~* Positive Double Blind Placebo Controlled Food Challenge (DBPCFC).~Exclusion Criteria (to consent):~* History of anaphylaxis to milk~* Use of probiotics~* Use in the previous 4 weeks of systemic steroids~* Use of systemic immunomodulatory treatment, including biologics with an immune target such as Xolair~* Known eosinophilic GI disorders~* Episode(s) of severe repetitive vomiting and lethargy prompting an emergency room visit and occurring within 4 hours of ingesting a milk protein (i.e. consistent with FPIES)~* Co-existing autoimmune or other chronic disease or serious health problem, including celiac disease, inflammatory bowel disease, malignancy, congenital, metabolic or genetic disorders or malformations~* Intention to exclusively breast feed~* Infants born at less than 36 weeks gestation (35 weeks + 6 days is considered 35 weeks gestation)~Exclusion Criteria (to randomization):~* Severe reaction to Milk Protein during the DBPCFC

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Days
- Healthy Volunteers: f

Study Arms:
- Amino Acid Formula (Type: PLACEBO_COMPARATOR): None
- EHCF (Type: ACTIVE_COMPARATOR): Extensively Hydrolyzed Casein Formula
- EHCF + LGG (Type: ACTIVE_COMPARATOR): Extensively Hydrolyzed Casein Formula + Lactobacillus GG

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues